

POSTER PRESENTATION

Open Access

Identification of novel immune checkpoints as targets for cancer immunotherapy

Galit Rotman^{1*}, Ofer Levy¹, Amir Toporik¹, Gady Cojocaru¹, Liat Dassa¹, Iris Hecht¹, Ilan Vaknin¹, Anat Oren¹, Zohar Tiran¹, Nora Tarcic¹, Sergey Nemzer¹, Tania Pergam¹, Amit Novik¹, Shirley Sameah-Greenwald¹, Joseph R Podojil², Stephen D Miller², Judith Leitner³, Peter Steinberger³, Eyal Neria¹, Zurit Levine¹

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Members of the B7/CD28 family of immune checkpoints, such as CTLA-4, PD1 and PDL-1, play critical roles in T cell regulation and have emerged as promising drug targets for cancer immunotherapy. Utilizing Compugen's predictive discovery platform, we identified novel members of this family that may serve as immune checkpoints. The therapeutic relevance of these proteins was confirmed following the validation of their immunomodulatory properties and their expression in various cancers. Here we present results obtained for two of our novel B7/CD28 family members: CGEN-15001T and CGEN-15022. Fusion proteins, consisting of the extracellular domain of the predicted proteins fused to an IgG Fc domain, display robust inhibition of T cell activation and therapeutic effects in T-cell driven animal models, EAE and CIA. The Fc fused protein of CGEN-15001T also showed enhancement of iTregs induction. Immunohistochemistry studies on a variety of healthy and malignant tissues indicate expression of both molecules in various types of epithelial and hematopoietic cancers, with each protein showing a unique expression pattern. Expression was also detected on tumor infiltrating immune cells. Based on their immunomodulatory activity and expression in malignant and immune cells, CGEN-15001T and CGEN-15022 show potential as targets for cancer immunotherapy.

Authors' details

¹Compugen Ltd, Tel Aviv, Israel. ²Microbiology-Immunology, Northwestern University, Chicago, IL, USA. ³Inst. Immunology, Medical University of Vienna, Vienna, Austria.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P135

Cite this article as: Rotman *et al.*: Identification of novel immune checkpoints as targets for cancer immunotherapy. *Journal for ImmunoTherapy of Cancer* 2013 **1**(Suppl 1):P135.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹Compugen Ltd, Tel Aviv, Israel
Full list of author information is available at the end of the article